Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review
Portfolio Pulse from
Vanda Pharmaceuticals Inc. has sent a letter to the FDA Commissioner highlighting issues with the FDA's review of their New Drug Application (NDA) for tradipitant, a treatment for gastroparesis.
January 08, 2025 | 9:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Vanda Pharmaceuticals has raised concerns about the FDA's review process for their drug tradipitant, intended for gastroparesis treatment. This could affect the approval timeline and investor sentiment.
The letter to the FDA suggests potential delays or issues in the approval process for tradipitant, which could negatively impact Vanda's stock price in the short term due to uncertainty around the drug's market entry.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100